140 related articles for article (PubMed ID: 18708434)
1. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.
Moyes VJ; Metcalfe KA; Drake WM
Eur J Endocrinol; 2008 Nov; 159(5):541-5. PubMed ID: 18708434
[TBL] [Abstract][Full Text] [Related]
2. Remission of acromegaly following long-term therapy with cabergoline: report of two cases.
Verhelst JA; Abrams PJ; Abs R
Pituitary; 2008; 11(1):103-7. PubMed ID: 17530416
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Selvarajah D; Webster J; Ross R; Newell-Price J
Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline treatment of acromegaly: a preliminary dose finding study.
Jackson SN; Fowler J; Howlett TA
Clin Endocrinol (Oxf); 1997 Jun; 46(6):745-9. PubMed ID: 9274706
[TBL] [Abstract][Full Text] [Related]
7. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Khandji AG; Post KD
Pituitary; 2004; 7(1):21-30. PubMed ID: 15638294
[TBL] [Abstract][Full Text] [Related]
9. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
Marzullo P; Ferone D; Di Somma C; Pivonello R; Filippella M; Lombardi G; Colao A
Pituitary; 1999; 1(2):115-20. PubMed ID: 11081189
[TBL] [Abstract][Full Text] [Related]
11. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
Muratori M; Arosio M; Gambino G; Romano C; Biella O; Faglia G
J Endocrinol Invest; 1997 Oct; 20(9):537-46. PubMed ID: 9413808
[TBL] [Abstract][Full Text] [Related]
12. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
15. IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.
Akirov A; Greenman Y; Glaser B; S'chigol I; Mansiterski Y; Eizenberg Y; Shraga-Slutzky I; Shimon I
Pituitary; 2018 Aug; 21(4):406-413. PubMed ID: 29728863
[TBL] [Abstract][Full Text] [Related]
16. Place of cabergoline in acromegaly: a meta-analysis.
Sandret L; Maison P; Chanson P
J Clin Endocrinol Metab; 2011 May; 96(5):1327-35. PubMed ID: 21325455
[TBL] [Abstract][Full Text] [Related]
17. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
Cozzi R; Attanasio R; Barausse M; Dallabonzana D; Orlandi P; Da Re N; Branca V; Oppizzi G; Gelli D
Eur J Endocrinol; 1998 Nov; 139(5):516-21. PubMed ID: 9849816
[TBL] [Abstract][Full Text] [Related]
19. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
Shimon I; Jallad RS; Fleseriu M; Yedinak CG; Greenman Y; Bronstein MD
Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
[TBL] [Abstract][Full Text] [Related]
20. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
